Elicio Therapeutics Shifts Focus to Metastatic Cancer with KRAS Immunotherapy

Elicio Therapeutics is repositioning its lead immunotherapy candidate, ELI-002, toward treating metastatic cancers, particularly those driven by KRAS mutations—a mutation present in about one-quarter of all solid tumors. The company, which has raised approximately $38.5 million in cash and financing since Q2 2024, is targeting a market estimated to include over 500,000 patients annually in the U.S. and Europe, including pancreatic, colorectal, and non-small cell lung cancers. Its pivot follows a Phase II trial, AMPLIFY-7P, which did not meet its primary disease-free survival endpoint compared to observation, but highlighted promising case series in metastatic pancreatic cancer. In a small cohort of three patients who progressed on ELI-002, all achieved complete radiographic and metabolic responses after combination therapy with chemotherapy, checkpoint inhibitors, and radiation—two responses lasting over nine months. Such outcomes are rare in pancreatic cancer, where complete responses typically occur in just 1–2 of 40–50 patients. The company’s Chief Scientific Officer, Pete DeMuth, emphasized that ELI-002’s lymph-node-targeted mechanism mitigates safety concerns common in broader immunotherapies. He also noted that metastatic pancreatic cancer represents a four- to five-times-larger patient population than adjuvant/neoadjuvant settings, offering a faster path to registration and reduced capital requirements. Elicio’s metastatic pancreatic cancer Phase I trial is planned for launch in Q4 2024, with initial efficacy data expected by Q1 2025. The company’s stock closed at $2.00 on September 14, 2026, down 2.44% from the prior close of $2.05, following an 87.5% decline over the past year. Analysts project a price target range of $10 to $23, though the firm’s current ratio of 2.77 and negative $37.71 million in leveraged free cash flow over the trailing twelve months reflect financial challenges. Elicio’s strategic pivot aligns with broader biotech trends, where metastatic indications are increasingly prioritized for unmet medical needs and accelerated clinical timelines.